



(51) International Patent Classification:

C07D 273/00 (2006.01) A61K 31/33 (2006.01)

A61P 35/00 (2006.01) C07D 491/08 (2006.01)

(21) International Application Number:

PCT/EP2022/076603

(22) International Filing Date:

25 September 2022 (25.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21199013.0 24 September 2021 (24.09.2021) EP

(71) Applicants: LEAD DISCOVERY CENTER GMBH

[DE/DE]; Otto-Hahn-Str. 15, 44227 Dortmund (DE). **QLI5 THERAPEUTICS GMBH** [DE/DE]; Otto-Hahn-Str. 15, 44227 Dortmund (DE).

(72) Inventors: KOCH, Uwe; Am Paß 6, 44227 Dortmund

(DE). **ZISCHINSKY, Gunther**; Herdecker Weg 16, 44229 Dortmund (DE). **UNGER, Anke**; Zehlendorfer Weg 12, 44388 Dortmund (DE). **NUSSBAUMER, Peter**; Henrietenweg 37, 44227 Dortmund (DE). **KLEBL, Bert**; Bittermarkstr. 85, 44229 Dortmund (DE). **CHOIDAS, Axel**; Kermelberg 19a, 58313 Herdecke (DE). **DINKEL, Klaus**; Wiesenstrasse 7, 67705 Trippstadt (DE). **ENGEL, Julian**; Wilhelmstr. 17, 44137 Dortmund (DE). **DEGENHART, Carsten**; Ardeystr. 145, 44225 Dortmund (DE). **HUBER, Robert**; Giggenbacherstr. 23, 81249 München (DE). **NAM, Kiyeon**; 605-2402, 248, Jeongjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13554 (KR). **KIM, Jaeseung**; 209-1903, 8, Samseong-ro 111-gil, Gangnam-gu, Seoul 06095 (KR). **SEO, Jeongja**; 101-703, 44, Madeul-ro1-gil, Nowon-gu, Seoul 01910 (KR). **LEE, Seung-Joo**; 303-1401, 177, Migeum-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13628 (KR). **JEON, Yeejin**; 112-901, 58, Mokgam-ro, Gwangmyeong-si, Gyeonggi-do 14295 (KR). **AHN, Wonyun**; 105-1102, 91, Pungdeokcheon-ro, Suji-gu, Yongin-si, Gyeonggi-do 16836 (KR).(74) Agent: **ARTH, Hans-Lothar**; ABK Patent Attorneys Jasminweg 9, 14052 Berlin (DE).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS



(57) **Abstract:** The present invention relates to certain macrocyclic compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease associated with and/or caused by proteasome or immunoproteasome, selected from a cancer, an infectious disease, an inflammatory disease, and autoimmune disease.

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE